Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Buti

Showing results (151-160 of 167) with videos related to

Pageof 17
Sort By:
Journal of Viral Hepatitis|March 27, 2007
Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patientsM Crespo, S Sauleda, J I Esteban, et al.
Alimentary Pharmacology & Therapeutics|November 30, 2016
Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO)M Buti, J L Calleja, S Lens, et al.
Gastroenterologia Y Hepatologia|September 25, 2004
[Genotype and phenotypic expression of hereditary hemochromatosis in Spain]A Pardo, E Quintero, Y Barrios, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 29, 2018
Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based studyJ M Fernández-Armenteros, X Gómez-Arbonés, M Buti-Soler, et al.
Journal of Viral Hepatitis|November 22, 2014
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trialM Buti, R Flisiak, J-H Kao, et al.
Alimentary Pharmacology & Therapeutics|October 13, 2017
HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patientsD Wong, M Littlejohn, L Yuen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under "Real-Life" ConditionsB Ruiz-Antorán, J M Pascasio, F Gea, et al.
Transplantation Proceedings|January 3, 2006
Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virusR Bárcena, S Del Campo, G Moraleda, et al.
Genes and Immunity|May 1, 2015
Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infectionJ Ampuero, J A del Campo, L Rojas, et al.
Journal of Viral Hepatitis|December 10, 2016
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohortS Alonso, M Riveiro-Barciela, I Fernandez, et al.
Pageof 17

Showing results (151-160 of 167) with videos related to

Sort By:
Pageof 17
Journal of Viral Hepatitis|March 27, 2007
Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patientsM Crespo, S Sauleda, J I Esteban, et al.
Alimentary Pharmacology & Therapeutics|November 30, 2016
Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO)M Buti, J L Calleja, S Lens, et al.
Gastroenterologia Y Hepatologia|September 25, 2004
[Genotype and phenotypic expression of hereditary hemochromatosis in Spain]A Pardo, E Quintero, Y Barrios, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 29, 2018
Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based studyJ M Fernández-Armenteros, X Gómez-Arbonés, M Buti-Soler, et al.
Journal of Viral Hepatitis|November 22, 2014
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trialM Buti, R Flisiak, J-H Kao, et al.
Alimentary Pharmacology & Therapeutics|October 13, 2017
HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patientsD Wong, M Littlejohn, L Yuen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under "Real-Life" ConditionsB Ruiz-Antorán, J M Pascasio, F Gea, et al.
Transplantation Proceedings|January 3, 2006
Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virusR Bárcena, S Del Campo, G Moraleda, et al.
Genes and Immunity|May 1, 2015
Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infectionJ Ampuero, J A del Campo, L Rojas, et al.
Journal of Viral Hepatitis|December 10, 2016
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohortS Alonso, M Riveiro-Barciela, I Fernandez, et al.
Pageof 17